Showing results (291-300 of 308) with videos related to
Sort By:
Pageof 31
Cancer|March 9, 2018
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNANeeraj Agarwal, Sumanta K Pal, Andrew W Hahn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.Cancer Cell|July 11, 2018
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal CancerGiulia Siravegna, Luca Lazzari, Giovanni Crisafulli, et al.Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric CancerSteven B Maron, Walid Chatila, Henry Walch, et al.Pageof 31